What is the Impact Factor of Expert Opinion on Emerging Drugs?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Expert Opinion on Emerging Drugs is 3.80, ranking in quartile Q2 of Web of Science (SCIE).

Is Expert Opinion on Emerging Drugs indexed in Web of Science or Scopus?

Yes, Expert Opinion on Emerging Drugs is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.908 (Q2) and an H-index of 59.

Who publishes Expert Opinion on Emerging Drugs and what is the Article Processing Charge (APC)?

Expert Opinion on Emerging Drugs is published by Taylor and Francis Ltd.. The estimated Article Processing Charge (APC) is approximately $3,290 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Expert Opinion on Emerging Drugs?

The official ISO-4 abbreviation of Expert Opinion on Emerging Drugs is "EXPERT OPIN. EMERGING DRUGS". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q2SCImago #5,701Top JournalReview JournalHybrid

Expert Opinion on Emerging Drugs

Abbreviation (ISO):EXPERT OPIN. EMERGING DRUGS

•

Identifier (ISSN):1472-8214(Print)/1744-7623(Online)

•

Publisher:Taylor and Francis Ltd.

Official Website Submission Portal Compare

Clarivate IF (2026)

3.8↑ +1.1

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIETop Tier

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Expert Opinion on Emerging Drugs

WoS Q2

Annual Impact Factor Metric

Current (2026):3.8

Scopus SJR & RankScopus Q2

0.908

#5,701

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

59 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

31articles/year

4.69% Gold OA•6.45% Original Research

Aims & Scope

Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.

Topics Covered (Recognized by AI)

Medicine99.9%Biology90.6%Internal medicine85.4%Pathology60.1%Genetics59.8%Chemistry46.1%Intensive care medicine44.6%Biochemistry43.5%Pharmacology43.2%Psychology38.9%Bioinformatics36.7%Immunology36.5%Psychiatry35.3%Surgery31.5%Disease27.3%Clinical trial27.1%Endocrinology25.3%Cancer23%Oncology21%

Primary Research Areas

Medicine Pharmacy

Official Website NLM PubMed Catalog SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank116/356

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank227/356

IndexSCIE

Category	Index	Rank	Quartile
PHARMACOLOGY & PHARMACY	JCRSCIE	116/356	Q2
PHARMACOLOGY & PHARMACY	JCISCIE	227/356	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF3.8

Articles / Year18

Total Citations1

2025

IF2.7

Articles / Year25

Total Citations77

2024

IF2.7

Articles / Year33

Total Citations274

2023

IF3.4

Articles / Year29

Total Citations199

2022

IF3.912

Articles / Year35

Total Citations354

Year	Impact Factor	Articles / Year	Total Citations
2026	3.8	18	1
2025	2.7	25	77
2024	2.7	33	274
2023	3.4	29	199
2022	3.912	35	354
2021	4.191	34	460
2020	2.807	42	871
2019	3.23	21	470
2018	3.579	30	874
2017	—	25	517
2016	—	40	1,023
2015	—	48	1,440

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #5,701Scopus Q2SCImago Profile

Scopus Coverage:2000-2025

•

Scopus Broad Areas:MedicinePharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q2

0.908

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

3.44

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,290 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations308

3-Year Documents96

Citable Documents83

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate54.7%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

PharmacologyQ2

Pharmacology (medical)Q2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区PHARMACOLOGY & PHARMACY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Expert Opinion on Emerging Drugs (abbr: EXPERT OPIN. EMERGING DRUGS, ISSN: 1472-8214) is a peer-reviewed international scholarly journal in the field of Medicine, published by Taylor and Francis Ltd. in England since 2001. The periodical holds a Journal Impact Factor (JIF) of 3.80, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.908 (Q2), an H-index of 59.

The journal enforces rigorous peer evaluation with a publication frequency of Quarterly, an annual output of approximately 31 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,290 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.